Needham analyst Michael Matson has maintained their neutral stance on TMDX stock, giving a Hold rating on September 18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Hold rating due to a combination of factors related to TransMedics Group’s recent performance data. The SRTR data for August 2025 suggests that the company’s transplant volumes were below the average monthly rate observed in the second quarter of 2025. Specifically, the average monthly transplant volume for July and August was estimated at 353, compared to 416 in the previous quarter.
Despite the potential for a 17% year-over-year increase in transplant volume and a 24% rise in US sales for the third quarter, the current estimates fall short of previous projections. The anticipated US sales of $130 million are below the earlier estimate of $145 million. Matson notes that these figures are based on incomplete data for the quarter, and there is a possibility for improvement in September. This uncertainty and the current shortfall in projections contribute to the Hold rating.
Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Merit Medical Systems. According to TipRanks, Matson has an average return of -4.7% and a 40.68% success rate on recommended stocks.
In another report released on September 18, Morgan Stanley also maintained a Hold rating on the stock with a $123.00 price target.